Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an announcement.
Paradigm Biopharmaceuticals held an investor webinar to update on its global Phase 3 clinical trial of iPPS for knee osteoarthritis. The company aims to address unmet medical needs with this therapy, which could significantly impact its market positioning and offer new treatment options for patients with inflammatory diseases.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health by developing pharmaceutical therapies. The company’s current focus is on developing injectable pentosan polysulfate sodium (iPPS) for treating diseases where inflammation is a major factor, such as osteoarthritis.
Average Trading Volume: 861,579
Technical Sentiment Signal: Buy
Current Market Cap: A$159M
See more insights into PAR stock on TipRanks’ Stock Analysis page.